A Phase 1 interventional study of Itraconazole and rifampicin in Drug Interaction, sponsored by Emalex Biosciences Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Emalex Biosciences Inc. · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single center, 2-Part, Phase 1, open-label, fixed-sequence, drug-drug interaction study designed to compare the PK of ecopipam when administered alone and in combination with itraconazole (Part 1) or rifampicin (Part 2) in healthy subjects.
Emalex Biosciences Inc. is the lead sponsor of 17 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 5 (42%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ecopipam 89.6 mg on Days 1 and 9 with repeat doses of itraconazole Days 6-16.
Drug: Itraconazole · Drug: Ecopipam
ecopipam 179.2 mg on Days 1 and 13 with repeat doses of rifampicin days 6-20.
Drug: rifampicin · Drug: Ecopipam
itraconazole 200 mg QD Days 6 to 16
rifampicin 600 mg QD Days 6 to 20
89.6 mg on Days 1 and 9 for Part 1 or 179.2 mg on Days 1 and 13 for Part 2
AUC0-inf of ecopipam when administered with itraconazole
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
AUC0-inf of ecopipam when administered without itraconazole
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
AUC0-inf of ecopipam when administered with rifampicin
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
AUC0-inf of ecopipam when administered without rifampicin
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
AUC0-t of ecopipam when administered with itraconazole
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
AUC0-t of ecopipam when administered without itraconazole
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
AUC0-t of ecopipam when administered with rifampicin
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
AUC0-t of ecopipam when administered without rifampicin
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
Cmax of ecopipam when administered with itraconazole
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
Cmax of ecopipam when administered without itraconazole
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
Cmax of ecopipam when administered with rifampicin
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
Cmax of ecopipam when administered without rifampicin
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
T½ el of ecopipam when administered with itraconazole
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
T½ el of ecopipam when administered without itraconazole
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
T½ el of ecopipam when administered with rifampicin
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
T½ el of ecopipam when administered without rifampicin
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
AUC0-inf of EBS-101-40853
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
AUC0-inf of ecopipam glucuronide
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
AUC0-inf of EBS-101-40853 glucuronide
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
AUC0-t of EBS-101-40853
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
AUC0-t of ecopipam glucuronide
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
AUC0-t of EBS-101-40853 glucuronide
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
Cmax of EBS-101-40853
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
Cmax of ecopipam glucuronide
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
Cmax of EBS-101-40853 glucuronide
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
T½ el of EBS-101-40853
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
T½ el of ecopipam glucuronide
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
T½ el of EBS-101-40853 glucuronide
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
AUC0-4 for ecopipam
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
AUC0-4 for EBS-101-40853
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
AUC0-4 for ecopipam glucuronide
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
AUC0-4 for EBS 101-40853 glucuronide
Up to 38 samples will be collected at the indicated time points for pharmacokinetic analysis
Time frame: Up to Day 21
Minimum Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score
Score from 0-5 where 0 is no response and 5 is responds readily. MOAA/S measures will be recorded at the indicated timepoints
Time frame: Up to Day 21
AUEC for Visual Analogue Scale (VAS)
Score from 0 - 100 where 0 is not sedated and 100 is very sedated. VAS measures will be recorded at the indicated timepoints.
Time frame: Up to Day 21
Maximum sedation for Visual Analogue Scale (VAS)
Score from 0 - 100 where 0 is not sedated and 100 is very sedated. VAS measures will be recorded at the indicated timepoints.
Time frame: Up to Day 21
AUEC for Reaction Time Index (RTI) score
Reaction time for subject to release the response button after presentation of target stimulus.
Time frame: Up to Day 21
Maximum sedation for Reaction Time Index (RTI) score
Reaction time for subject to release the response button after presentation of target stimulus.
Time frame: Up to Day 21
Safety and tolerability as demonstrated by AEs with itraconazole
Subjects will be continually monitored for adverse events
Time frame: Up to Day 30
Safety and tolerability as demonstrated by AEs without itraconazole
Subjects will be continually monitored for adverse events
Time frame: Up to Day 30
Safety and tolerability as demonstrated by AEs with rifampicin
Subjects will be continually monitored for adverse events
Time frame: Up to Day 30
Safety and tolerability as demonstrated by AEs without rifampicin
Subjects will be continually monitored for adverse events
Time frame: Up to Day 30
Safety and tolerability as demonstrated by Systolic blood pressure (SBP) and diastolic blood pressure (DBP) with itraconazole (mmHG)
Blood pressure will be assessed as part of vital signs
Time frame: Up to Day 21
Safety and tolerability as demonstrated by Systolic blood pressure (SBP) and diastolic blood pressure (DBP) without itraconazole(mmHG)
Blood pressure will be assessed as part of vital signs
Time frame: Up to Day 21
Safety and tolerability as demonstrated by Systolic blood pressure (SBP) and diastolic blood pressure (DBP) with rifampicin(mmHG)
Blood pressure will be assessed as part of vital signs
Time frame: Up to Day 21
Safety and tolerability as demonstrated by Systolic blood pressure (SBP) and diastolic blood pressure (DBP) without rifampicin(mmHG)
Blood pressure will be assessed as part of vital signs
Time frame: Up to Day 21
Heart rate with itraconazole (beats/minute)
Heart rate will be assessed as part of vital signs
Time frame: Up to Day 21
Heart rate without itraconazole (beats/minute)
Heart rate will be assessed as part of vital signs
Time frame: Up to Day 21
Heart rate with rifampicin (beats/minute)
Heart rate will be assessed as part of vital signs
Time frame: Up to Day 21
Heart rate without rifampicin (beats/minute)
Heart rate will be assessed as part of vital signs
Time frame: Up to Day 21
Respiratory rate pressure with itraconazole (breaths/minute)
Respiratory rate will be assessed as part of vital signs
Time frame: Up to Day 21
Respiratory rate without itraconazole (breaths/minute)
Respiratory rate will be assessed as part of vital signs
Time frame: Up to Day 21
Respiratory rate with rifampicin (breaths/minute)
Respiratory rate will be assessed as part of vital signs
Time frame: Up to Day 21
Respiratory rate without rifampicin (breaths/minute)
Respiratory rate will be assessed as part of vital signs
Time frame: Up to Day 21
Oral temperature with itraconazole (degrees Celsius)
Temperature will be assessed as part of vital signs
Time frame: Up to Day 21
Oral temperature without itraconazole (degrees Celsius)
Temperature will be assessed as part of vital signs
Time frame: Up to Day 21
Oral temperature with rifampicin (degrees Celsius)
Temperature will be assessed as part of vital signs
Time frame: Up to Day 21
Oral temperature without rifampicin (degrees Celsius)
Temperature will be assessed as part of vital signs
Time frame: Up to Day 21
Electrocardiogram (ECG) parameters: PR, RR, QRS, QT, and QT interval corrected for heart rate using Fridericia's formula (QTcF) with itraconazole (Milliseconds)
Twelve-lead ECGs will be obtained at the indicated timepoints
Time frame: Up to Day 21
Electrocardiogram (ECG) parameters: PR, RR, QRS, QT, and QT interval corrected for heart rate using Fridericia's formula (QTcF) without itraconazole (Milliseconds)
Twelve-lead ECGs will be obtained at the indicated timepoints
Time frame: Up to Day 21
Electrocardiogram (ECG) parameters: PR, RR, QRS, QT, and QT interval corrected for heart rate using Fridericia's formula (QTcF) with rifampicin (Milliseconds)
Twelve-lead ECGs will be obtained at the indicated timepoints
Time frame: Up to Day 21
Electrocardiogram (ECG) parameters: PR, RR, QRS, QT, and QT interval corrected for heart rate using Fridericia's formula (QTcF) without rifampicin (Milliseconds)
Twelve-lead ECGs will be obtained at the indicated timepoints
Time frame: Up to Day 21
Safety and tolerability as demonstrated by the Columbia Suicide Severity Rating Scale (C-SSRS)
C-SSRS to be administered at the indicated timepoints
Time frame: Up to Day 21
Values of white blood cell (WBC), neutrophils, lymphocytes, monocytes, eosinophils, basophils and platelets (1000/mm3)
Blood samples will be collected for the assessment of hematology parameters
Time frame: Up to Day 21
Value of hematocrit (percent)
Blood samples will be collected for the assessment of hematology parameters
Time frame: Up to Day 21
Value of hemoglobin (g/dL)
Blood samples will be collected for the assessment of hematology parameters
Time frame: Up to Day 21
Red blood cell (RBC) count (M/mm3)
Blood samples will be collected for the assessment of hematology parameters
Time frame: Up to Day 21
Values of sodium, potassium, chloride (mmol/L)
Blood samples will be collected for the assessment of clinical chemistry parameters
Time frame: Up to Day 21
Values of urea, phosphorus, calcium, glucose, and total, direct and indirect bilirubin (mg/dL)
Blood samples will be collected for the assessment of clinical chemistry parameters
Time frame: Up to Day 21
Values of albumin and total protein (g/dL)
Blood samples will be collected for the assessment of clinical chemistry parameters
Time frame: Up to Day 21
Values of alanine aminotransferase (ALT), aspartate aminotransferase (AST),alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), creatininephosphokinase (CPK), and creatinine (U/L)
Blood samples will be collected for the assessment of clinical chemistry parameters
Time frame: Up to Day 21
Values of urine specific gravity
Urine samples will be collected for the assessment of urine parameters
Time frame: Up to Day 21
Values of urine pH
Urine samples will be collected for the assessment of urine parameters
Time frame: Up to Day 21
Values of urine glucose
Urine samples will be collected for the assessment of urine parameters
Time frame: Up to Day 21
Values of urine protein
Urine samples will be collected for the assessment of urine parameters
Time frame: Up to Day 21
Values of urine blood
Urine samples will be collected for the assessment of urine parameters
Time frame: Up to Day 21
Values of urine ketones
Urine samples will be collected for the assessment of urine parameters
Time frame: Up to Day 21
Values of urine bilirubin and nitrite
Urine samples will be collected for the assessment of urine parameters
Time frame: Up to Day 21
Values of urobilinogen
Urine samples will be collected for the assessment of urine parameters
Time frame: Up to Day 21
Values of urine leukocyte esterase by dipstick
Urine samples will be collected for the assessment of urine parameters
Time frame: Up to Day 21
Ran from Jan 2024 to primary completion in May 2024, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Itraconazole · Rifampin · Ecopipam
Emalex Biosciences Inc.